Zevra to face FDA adcomm in August over previously rejected rare disease drug

The FDA’s recently created Genetic Metabolic Diseases Advisory Committee will meet on Aug. 2 to review Zevra Therapeutics’ arimoclomol as a treatment for the rare and fatal genetic disorder known as Niemann-Pick disease type C.

The drug was rejected once before, in 2021, and the FDA’s decision to Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertise With Biotech Networks